Antibodies

09 Jan 2017 Kymab Expands Infectious Disease Programmes
09 Jan 2017 FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
06 Jan 2017 Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia
06 Jan 2017 FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
05 Jan 2017 Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma
05 Jan 2017 Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)
05 Jan 2017 Ambrx and MabSpace Biosciences to Collaborate on Novel Antibody Drug Conjugates
05 Jan 2017 ProMIS Neurosciences declares PMN 310 its first lead product for development in Alzheimer's disease
05 Jan 2017 Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)
05 Jan 2017 Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency
04 Jan 2017 Compugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity
04 Jan 2017 OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients
03 Jan 2017 Prima Announces New Product Candidate IMP761 -- A LAG-3 Agonist Antibody
03 Jan 2017 Glenmark Pharmaceuticals Receives FDA Clearance of IND for GBR 1302-BEAT™ Phase I Trial
01 Jan 2017 BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317
29 Dec 2016 Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1
27 Dec 2016 Immunomedics Announces Achievement of Patient Enrollment Into Single-Arm Phase 2 Study With Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer
27 Dec 2016 Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A)
23 Dec 2016 New Research Suggests Role for Aravive Biologics’ Anti-AXL Candidate for Increasing Tumor Sensitivity to Radiation and Check-point Inhibitors
23 Dec 2016 Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy
22 Dec 2016 Chugai’s Bispecific Antibody “Emicizumab” for Hemophilia A Meets Primary Endpoint in Phase lll Study
22 Dec 2016 Positive Phase III Results of Genentech’s Investigational Medicine Ocrevus™ (Ocrelizumab) Published in New England Journal of Medicine
22 Dec 2016 Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris(R)) for the Prevention of Delayed Graft Function (DGF) After Kidney Transplantation
22 Dec 2016 Merrimack Stops the Phase 2 HERMIONE Trial of MM-302 in HER2-Positive Metastatic Breast Cancer Patients
21 Dec 2016 Janssen Submits Two Applications To FDA Seeking Approval Of Simponi Aria® (Golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top